Author Archives: admin

Disruptive discovery method for inhibitors of protein-protein interactions

Protein-Protein interactions (PPIs) are central to most essential cellular mechanisms including gene expression, protein translocation, cell cycle progression and signal transduction. Bellón-Echeverría et al. published in Scientific Reports a proof of concept employing MultiBacMam to identify new small-molecule inhibitors of the CDK5-p25 protein-protein interaction. The method is generally applicable to any multiprotein cascade important in drug discovery.

EBOLA RNA POLYMERASE PRODUCED USING MULTIBAC

Tchesnokov et al. published in Scientific Reports (DOI: :10.1038/s41598-018-22328-3) a production system for Ebola Virus RNA-Dependent RNA Polymerase Complex using the MultiBac system, providing a powerful discovery system for this key drug target.

NEW SYNBAC DEVELOPMENT MILESTONE

Geneva Biotech and partners have recorded >70% increase in baculovirus DNA stability in scale up experiments to 100L using second generation SynBac genomes. DNA stability was found to strongly correlate (r = 0.91) with expression yield of multiple different test proteins.

Competent Cell Partner in North America

IG-Logo

Intact Genomics is a world leader of ultra-high competent cell production and BAC (bacterial artificial chromosome) library related technologies. Intact has partnered with Geneva Biotech to offer North American customers competent cells containing Geneva Biotech’s viral genomes. See their Geneva Biotech partnered products here INTACT GENOMICS

MTORC1 STRUCTURE SOLVED USING MULTIBAC

Aylett et al. published in Science (DOI: 10.1126/science.aaa3870) the structure of key drug target mTORC1 using the MultiBac system, providing critical information on the function and intricate regulation of this important enzyme which is implicated in common human diseases including cancer and diabetes.